KR100486963B1 - The health-supporting food having the effect of diabetes mellitus and its preparation method - Google Patents
The health-supporting food having the effect of diabetes mellitus and its preparation method Download PDFInfo
- Publication number
- KR100486963B1 KR100486963B1 KR10-2002-0057661A KR20020057661A KR100486963B1 KR 100486963 B1 KR100486963 B1 KR 100486963B1 KR 20020057661 A KR20020057661 A KR 20020057661A KR 100486963 B1 KR100486963 B1 KR 100486963B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- ginseng
- parts
- deep
- water
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 44
- 235000013305 food Nutrition 0.000 title description 10
- 230000000694 effects Effects 0.000 title description 9
- 238000002360 preparation method Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 241000411851 herbal medicine Species 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 5
- 239000013535 sea water Substances 0.000 claims description 41
- IQULGZQMMPRBLA-UHFFFAOYSA-N 2-carboxyethylgermanium Chemical compound OC(=O)CC[Ge] IQULGZQMMPRBLA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012676 herbal extract Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 235000013311 vegetables Nutrition 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 4
- 235000011613 Pinus brutia Nutrition 0.000 claims description 4
- 241000018646 Pinus brutia Species 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 abstract description 69
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 67
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 67
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 abstract description 43
- 229910052732 germanium Inorganic materials 0.000 abstract description 30
- 235000015872 dietary supplement Nutrition 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 12
- 230000003449 preventive effect Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 4
- 229940010454 licorice Drugs 0.000 abstract description 4
- 241000208340 Araliaceae Species 0.000 abstract 17
- 240000000724 Berberis vulgaris Species 0.000 abstract 1
- 235000016068 Berberis vulgaris Nutrition 0.000 abstract 1
- 240000008564 Boehmeria nivea Species 0.000 abstract 1
- 244000018436 Coriandrum sativum Species 0.000 abstract 1
- 235000002787 Coriandrum sativum Nutrition 0.000 abstract 1
- 241000242583 Scyphozoa Species 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 230000002265 prevention Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 239000010440 gypsum Substances 0.000 description 5
- 229910052602 gypsum Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 239000000446 fuel Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- -1 hydrogen ions Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000014679 Morus rubra var. rubra Nutrition 0.000 description 1
- 235000014677 Morus rubra var. tomentosa Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000011646 bottled functional water Nutrition 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 241001233061 earthworms Species 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 정제된 심층수(선도액), 유기 게르마늄(Ge-132) 및 한약재를 주재료로 하여 당뇨병에 우수한 치료 및 예방 효과를 나타내는 건강보조식품에 관한 것으로, 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 정제된 심층수(선도액) 60 ∼ 74.5중량%, 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 흥매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상의 한약재 추출물 25 ∼ 39.5중량% 및 유기 게르마늄(Ge-132) 0.5 ∼ 15중량%로 구성되어지되 정제된 심층수(선도액), 한약재 추출물 및 유기 게르마늄(Ge-132)을 혼합하여 본 발명의 건강보조식품을 얻고, 이를 복용하게 하므로서 당뇨병에 우수한 치료 및 예방 효과를 얻을 수 있었다.The present invention relates to a health supplement having excellent therapeutic and preventive effects on diabetes using refined deep water (lead solution), organic germanium (Ge-132) and herb medicine as main ingredients. 60 to 74.5% by weight of purified deep water mixed with an appropriate amount of water and a suitable amount of water, Ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng 25-39.5% by weight of at least six kinds of herbal medicine extracts selected from the group consisting of barberry, jellyfish, gojiji, coriander, licorice, chinchon, and ramie, and 0.5-15% by weight of organic germanium (Ge-132) Refined deep water (lead solution), Chinese medicine Gaining chulmul and organic germanium (Ge-132) the dietary supplement of the present invention by mixing, to obtain an excellent therapeutic and preventive effects on diabetes hameuroseo to take them.
Description
본 발명은 정제된 심층수(선도액), 유기 게르마늄(Ge-132) 및 한약재를 주재료로 하여 당뇨병에 우수한 치료 및 예방 효과를 나타내는 건강보조식품 및 이의 제조 방법에 관한 것으로, 좀 더 구체적으로는 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 정제된 심층수(선도액) 60 ∼ 74.5중량%, 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상의 한약재 추출물 25 ∼ 39.5중량% 및 유기 게르마늄(Ge-132) 0.5 ∼ 15중량%로 구성되는 것을 특징으로 하는 당뇨병에 우수한 치료 및 예방 효과를 갖는 건강보조식품 및 이의 제조방법에 관한 것이다.The present invention relates to a health supplement food having excellent therapeutic and preventive effects on diabetes and a method for producing the same, and more particularly, to a health supplement food having purified water (purified liquid), organic germanium (Ge-132) 60 to 74.5% by weight of purified deep water (purified liquid) obtained by purifying 600-m deep water and 1400 m deep water and mixing them at an appropriate ratio, Deck, Buddhist temple, Buddhist temple, Buddhist temple, Buddhist temple, Buddhist temple, Buddhist temple, Buddhist temple, Buddhist temple, 25 to 39.5% by weight of at least six kinds of medicinal plant extracts selected from the group consisting of ginseng, ginseng, ginseng, seaweed, barbuch, geranium, ginger, ginger, licorice, 0.5 to 15% by weight It relates to the excellent care and health supplements and a method has a preventive effect on diabetes that is characterized.
이 세상 모든 동력기관은 움직이기 위해서는 연료가 있어야 하듯이, 모든 동물이 활동을 하기 위해서는 에너지를 발생시킬 수 있는 연료를 필요로 하는데 가장중요한 연료는 바로 포도당이다.All power engines in the world need fuel to move, and all animals need fuel to generate energy, which is the most important fuel.
사람도 바로 이 포도당을 얻기 위해 음식을 섭취하고 이것을 잘게 부수어 소화시킨 후 그 속에 있는 포도당을 혈액 내로 흡수하지만, 포도당이 우리 몸에서 쓰이기 위해서는 한가지 단계가 더 필요하다. 즉 췌장(정확히는 췌장 내의 랑겔한스섬의 베타세포)에서 분비되는 인슐린이라는 효소가 포도당을 우리 몸에서 잘 사용할 수 있도록 도와 주어야 비로소 우리 몸은 포도당을 연료로 사용하게 되는데 당뇨병은 바로 이 과정에서 문제가 생기는 병으로, 음식물 속에 들어 있던 포도당이 혈액 내로 들어 온 후 인술린 분비기관에 이상이 생겨 우리 몸에서 사용되지 못하면 혈액 속의 포도당 농도는 점점 올라가 결국 물과 함께 소변으로 나가게 된다.A person consumes food to get this glucose, digests it, digests it, absorbs glucose into the blood, but glucose needs one more step to be used in our bodies. In other words, an enzyme called insulin secreted from the pancreas (precisely the beta cells of the Rangelands island in the pancreas) must help us to use glucose in our bodies before we use glucose as fuel. Diabetes is a problem in this process When the glucose in the food comes into the blood and the insulin secretory organ is abnormally developed, the concentration of glucose in the blood gradually increases and eventually goes out to the urine with the water.
즉, 당뇨병이란 인슐린량(量)의 부족으로 혈액 중의 포도당(혈당)이 정상인보다 그 농도가 높아져서 소변에 포도당을 배출하는 만성질환으로서, 췌장의 랑게르한스섬의 B 세포에서 분비되는 인슐린의 부족, 뇌하수체전엽 · 부신(副堅) · 갑상선 등의 내분비선 기능항진(機能元進), 중추신경 특히 시상하부(視床下部)의 병변 등을 원인으로 들 수 있는데, 이들 인자(因子)가 합쳐져서 발병하는 것으로 생각되고 있고, 병인(病因)으로는 유전적 소인(素因)이 중요하며, 특히 소아나 나이 어린 환자의 경우에는 대부분이 유전과 관계가 있다고 볼 수 있고, 식생활도 발병과 밀접한 관계가 있다. 이것은 총칼로리 · 고단백 · 고지방식이 관계하는 것으로 추측되며, 더욱이 환자의 1/3에서 반수 가까이가 비만증이라는 점에서 비만과의 관계가 주목되고 있다.In other words, diabetes is a chronic disease in which glucose (blood sugar) in the blood is higher than that of a normal person due to a shortage of insulin amount (amount) and discharges glucose into the urine. As a result, insulin is secreted from B cells of the pancreas Langerhans islet, · Adrenal gland · Thyroid gland and function of the endocrine gland (functional origin), central nervous system, especially the hypothalamus (hypothalamus) is the cause of such factors, these factors are thought to be caused by the combination Genetic predisposition is important as an etiologic factor. Especially, in the case of pediatric or young patients, most of them are related to heredity, and the diet is closely related to the onset. This is thought to be related to total calorie, high protein, high fat diet, and more than half of the patients are obese.
한편, 젊은층의 당뇨병 환자 중에는 야윈 사람이 많은 것도 사실이고, 중년이후의 비만자의 당뇨병이 체중의 조절만으로 가볍게 낫는 점으로 미루어 비만의 병인적 의의에 대해서는 의론의 여지가 있으며, 일부 학자는 반대로 당뇨병이 비만의 원인이라고 보고 있으며, 임신을 계기로 발병하는 경우도 있어 임신도 어떤 메커니즘에 의하여 당뇨병을 일으키는 한 인자가 되는 것으로 유추되고 있고, 발병하는 연령은 대부분이 중년 이후로서 특히 40 ~ 60대에 많다. 발생빈도는 연령이 증가함에 따라 발병률이 커지고, 여성보다 남성에게 많으며, 육체 노동자보다 정신노동자에게 많다.On the other hand, there are many lean people among the diabetic patients in the younger age, and since the obesity diabetic after middle age is lightly cured only by the weight control, there is room for argument about the sickness of obesity, It is thought to be the cause of obesity. In some cases, the pregnancy may be caused by diabetes mellitus by some mechanisms, and the age of onset is mostly after middle age, especially in the 40s to 60s . The frequency of incidence increases with age, is more prevalent among males than females, and is higher among mentally retarded workers than manual workers.
당뇨병의 초기 주요 증세는 다뇨(多尿), 갈증, 나른함, 다식(多食), 체중감소 등이고, 이 중에서 갈증이 가장 많이 나타나고 다음으로 나른함, 다뇨의 순이 며, 이 밖에 음부소양, 월경이상, 성욕감퇴를 비롯하여 치조농루(齒檀膿漏)나 충치로 인해 치아가 빠지는 일이 있다.The first major symptoms of diabetes were polyuria, thirst, drowsiness, multiple diet, and weight loss. Among them, thirst was the most common, followed by lingering, followed by polyuria. In addition, Teeth may be lost due to loss of libido, tooth decay, or tooth decay.
합병증에 의한 증세로는 신경통, 지각이상, 시력장애 및 피부질환(부스럼, 멍울, 종기, 화농증, 습진) 등이 있고, 당뇨병을 장기간 방치하거나 치료를 적절히 하지 못하면, 외과수술, 감염, 발열 등 때문에 당뇨병 증세가 급격히 악화되어 당뇨병성 아시도시스(acidosis)로 진전되는 경우가 있다.Symptoms caused by complications include neuralgia, tardive dysfunction, visual disturbances, and skin diseases (swelling, lump, boils, anemia, eczema) As a result, the diabetic condition rapidly worsens and progresses to diabetic acidosis.
당뇨병성 아시도시스는 당뇨병성 혼수(昏垂)라고도 하며, 당뇨병의 고혈당으로 인한 의식장애인데, 주로 젊은 층의 당뇨병 환자에게서 많이 볼 수 있으며, 이것을 일으키는 원인으로는 부적당한 치료, 특히 인슐린 주사의 중단과 발열, 감염, 수술 등을 들 수 있고, 증세는 그보다 먼저 다뇨, 갈증, 나른함 등의 당뇨병 증세가 심해지고 선하품, 메스꺼움, 구토증 등이 나타나며 탈수현상이 두드러지고, 호흡이 가빠지며 호흡 횟수도 늘어나며, 의식장애는 무관심의 정도로부터 혼수에 이르기까지 여러 단계가 있다.Diabetic acidosis is also known as diabetic coma and is a congenital anomaly caused by hyperglycemia of diabetes. It is mainly seen in diabetic patients in the younger age, and the cause of this is inappropriate treatment, especially the interruption of insulin injections The symptoms of diarrhea, thirst, and loneliness are more severe and the symptoms of nausea, nausea, and vomiting occur. The symptoms of dehydration are prominent, the breathing becomes worse, the number of breathing increases, Consciousness disorders range from indifference to coma.
당뇨병에 병발하는 질환에 중요한 것으로는 당뇨병성 혈관장애, 신경장애, 감염증이 있으며, 당뇨병성 혈관장애로 대동맥, 관동맥, 하지의 혈관 등 비교적 굵은 혈관의 동맥경화와 망막, 신장(사구체) 등의 세소혈관에 동맥경화증의 병변 즉, 심장에는 관동맥경화증, 신장에는 사구체경화증, 눈에는 망막증이 생기며, 증세로는 고혈압, 심근경색, 협심증, 단백뇨, 신부전, 시력장애, 하지괴저 등이 나타나고, 당뇨병성 신경장애로 탄수화물 및 지질중간대사의 이상으로 인해 말초신경장애 즉, 건반사의 저하, 소실, 지각장애, 사지동통 등의 증세가 나타난다. 특히, 하지에 야간의 근육통과 같은 증세를 호소하는 일이 있고 발바닥의 작열감, 통각과민, 촉각둔마 등을 호소하기도 하고, 보통은 좌우대칭성이며 운동장에는 드물고, 그 밖에 자율신경장애로서 동공의 좌우부동, 발한 이상, 음위, 잔뇨감, 배뇨지연, 뇨폐, 변비, 설사 등을 볼 수 있다.Diabetes-related vascular disorders, neurological disorders, and infectious diseases are important in diseases associated with diabetes. Diabetic vascular disorders are caused by atherosclerosis of relatively large blood vessels such as aorta, coronary artery, and lower limb and retinal and renal (glomerular) Myocardial infarction, angina pectoris, proteinuria, renal failure, visual disturbance, lower gangrene, and diabetic neuropathy are present in the blood vessels of atherosclerotic lesions, that is, the heart has atherosclerosis, the kidney has glomerulosclerosis and the eye has retinopathy. The disorder is caused by abnormalities of carbohydrate and lipid middle metabolism, such as peripheral neuropathy, such as lowering of the key junction, loss of function, perception disorder, and limb pain. Especially, it appeals to the legs like the muscular pain of the night, and it appeals to the burning sensation of the sole, hyperalgesia, tactile dullness, etc. It is usually symmetrical and is rare in the playground. In addition, , Sweating abnormality, soundness, restlessness, delayed urination, urinary bladder, constipation, and diarrhea.
감염증으로 당뇨병에 감염증이 합병하는 빈도가 높은 데, 그 이유는 분명하지 않으나 혈액, 조직액의 당함량 증가, 감염에 대한 혈액의 저항성 감퇴, 세포의 영양상태 저하 등을 들 수 있으며, 감염증에는 요로감염증인 신우신염, 피부감염으로서 농피증, 부스럼, 종기, 모낭주위염, 습진과 그 밖에 여성 음부의 칸디다증 등이 있다.The incidence of infectious diseases in diabetes mellitus is high due to the infectious disease. The reason for this is not clear, but the increase in sugar content of blood and tissue fluid, the decrease of blood resistance to infection, the decrease of nutritional status of cells, Infections such as pyelonephritis, skin infection, scurvy, swelling, swelling, periarcitis, eczema and candidiasis in the female genitalia.
당뇨병은 조절은 할 수 있지만 완치는 불가능한 것으로 알려져 있고, 당뇨병치료의 목표는 당뇨병의 진행을 정지시킴과 동시에 당뇨병에 빈발하는 합병증의 발생 및 진전을 예방하는 데 있는 것으로, 이를 위해 우선 식이요법을 실시하고 그것으로 충분히 조절할 수 없는 경우에는 인슐린 요법, 또는 내복약 치료를 실시한다.It is known that diabetes can be controlled but it is impossible to cure. The goal of diabetes treatment is to stop the progression of diabetes and to prevent the occurrence and progress of complications frequently occurring in diabetes. And if it can not be controlled enough, insulin therapy, or treatment of internal medicine.
한편, 심층수(선도액)란 해양학적 관점에서 볼 때 해저 1000m 이하의 깊이에 있는 바닷물을 의미하며, 광합성에 의한 유기물 생성이 일어나지 않고 분해가 탁월하며 겨울철 해수 수직 혼합(海水垂直混合)작용이 도달하는 심도(深度)의 이하에 있는 해수로서 바닷물의 깊이에 따라 성분이 다르고, 화학적, 생물학적 위험 및 환경오염 등에 영향을 거의 받지 않아 대단히 깨끗한 물이며, 전형적으로 높은 물리적 안전성을 가진 대단위의 물분자들이 집합체로 뭉쳐져서 낮은 온도에서 형성되어 지고, 대량의 미량원소와 미네랄 등을 포함하고 있을 뿐만 아니라 무기영양소금이 포함되어 있어 물부영양화 현상이 뚜렷하여 건강음료로서 사용되어 질 뿐만 아니라 신선한 제품, 음식, 살아있는 조직(장기)의 신선도를 유지시켜주고 피부 표면의 활력을 증진시키는 피부 보호 기능까지 하는 것으로 알려지고 있다.On the other hand, deep sea water (leading solution) means seawater at a depth of less than 1000 m from the oceanographic point of view. It does not produce organic matter by photosynthesis and is excellent in decomposition, and the vertical seawater vertical mixing (Depth), which is very clean water with little or no effect on chemical, biological hazards, environmental pollution, etc. due to the depth of seawater, and large water molecules, typically with high physical safety, It is not only used as a health drink but also because it contains a large amount of trace elements and minerals as well as an inorganic nutrient salt, Maintains the freshness of living tissue (organs) and promotes vitality of the skin surface It is known to protect skin.
특히, 기능성 생수 제조나 화장품 생산에 활용되고, 해조류 배양 및 어류사육, 어장 비옥화, 종묘생산 등 수산분야와 화장품, 생수, 비누, 소금, 조미료 등 식품 개발, 의약품 개발, 농업 및 공업분야 등에 활용이 기대되고, 일본에서는 심층수(선도액)를 사용해 만든 부두, 된장, 청주, 절인 반찬, 스포츠 드링크 등이 출시되어 호평을 받고 있다.Especially, it is used in functional bottled water production and cosmetics production. It is used for food development such as seaweed culture, fish breeding, fertilizing of fishery field, seedling production, cosmetics, bottled water, soap, salt and seasoning, medicine development, agriculture and industrial fields And in Japan, puddings, miso, sake, pickled side dishes, sports drinks, etc. made using deep seawater (lead solution) have been popular and popular.
그러나, 아직까지 심층수(선도액)에 대한 많은 연구가 이루어지지 않아 다양한 용도로의 적용이 미미한 상황이고, 당뇨병의 치료와 예방을 위한 용도로 적용된 사례는 전무한 실정이다.However, since many studies on deep seawater have not been conducted yet, application to diverse applications is very limited, and there is no such application for the treatment and prevention of diabetes.
또한, 한약재들은 다양한 임상 경험을 토대로 하여 다양한 증상에 적용되는 많은 약재들이 있으나, 당뇨병에 전문적으로 적용되는 예는 거의 없었고, 단순한 증상에 따라 임상적인 배합이 적용되고 있는 실정이다.In addition, there are many medicinal herbs which are applied to diverse symptoms based on various clinical experiences, but there are few cases where diabetes is applied professionally, and clinical combinations are applied according to simple symptoms.
그리고, 원자번호 32, 원자량 72.59의 게르마늄은 금속아닌 아금속 원소로 흙속이나 식물에도 함유되어 있으며, 한국 인삼에는 4,189ppm, 마늘 754ppm, 구기자 124ppm, 컴프리 152ppm, 산두근 257ppm이 함유되어 있는데, 게르마늄이 현존하는 항암제와는 다른 차원의 제암효과가 있는 것은 모두가 게르마늄이 지닌 생체내에서 산소를 놀랍도록 풍부하게 해주는 작용과 인터페론 유도체로서의 역할 때문임이 연구 결과 밝혀졌다.In addition, germanium of atomic number 32 and atomic weight of 72.59 is a metallic element which is not a metal but contained in dirt and plants. Korean ginseng contains 4,189ppm, garlic 754ppm, gugija 124ppm, compri 152ppm, and mountain peel 257ppm. The researchers found that all of the different effects of anticancer chemotherapy are due to their ability to enrich oxygen in the body of germanium and to act as interferon derivatives.
생체란 보는 관점에 따라서는 전기의 극초미립자의 응집체라고 할 수 있다.The living body can be said to be an agglomeration of super-fine particles of electricity depending on the viewpoint.
각 기관, 각 부분은 각각 고유의 응집체로서 기능하고 있다. 때문에 각 부분은 정해진 전위가 있고, 그 전위가 뒤틀린 것이 질병이며, 뇌파측정기나 심전도는 이 전위의 변화를 측정함으로써 장애를 찾아내는 기기이고, 이 뒤틀린 전위를 바로 잡는데 게르마늄이 놀라운 역할을 한다.Each organ and each part functions as a unique aggregate. Therefore, each part has a fixed potential, and its dislocation is a disease. EEG or electrocardiogram is a device to detect the disorder by measuring the change of this potential, and germanium plays a remarkable role in correcting this twisted potential.
예를 들어, 암세포의 전위를 살펴보면 다른 정상세포의 전위와는 판이하게 다르다. 암세포는 맹렬한 속도로 세포증식을 계속하기 때문에 그 전위가 높고 심하게 격변하고 있지만 게르마늄은 그 높은 전위를 지닌 암세포로부터 전자를 빼앗아 전위를 낮추는 작용을 하므로서 진행중인 이상세포(암세포)의 활동을 중지시키는 역할을 하며, 암의 전이를 막는 이유이기도 하다.For example, when looking at the potential of cancer cells, it differs significantly from that of other normal cells. Cancer cells continue to proliferate at a violent rate, so their potential is high and they are seriously catastrophic. However, germanium has the role of disrupting the progression of abnormal cells (cancer cells) by lowering the potential by depriving electrons from cancer cells with high potential It is also a reason to prevent cancer metastasis.
게르마늄은 물론 혈액을 비롯한 각 세포는 반도체의 성질을 지니고 있는데 반도체끼리는 그 전자물성으로 보아 공존할 수 없기 때문에 여분의 게르마늄이 체내에 축적될 우려가 전혀 없으며 축적될 수 없다는것은 아무리 많이, 장기간 투여해도 여분의 게르마늄은 배설되기 때문에 부작용이 없다는 뜻이기도 하다.Each cell, including blood, as well as germanium, has the property of semiconductors. Since semiconductor materials can not coexist with each other due to their electronic properties, there is no fear that extra germanium accumulates in the body. Extra germanium is also excreted, which means there are no side effects.
최근 유기(有機) 게르마늄에 대한 관심이 높아지면서 그의 뛰어난 효능이 인정됨에 따라 기능성 치유물질로 높은 평가받고 있으며, 폐암, 방광암, 유암, 노이로제, 천식, 당뇨병, 고혈압증, 심부전, 축농증, 신경통, 백혈병, 뇌연화증, 자궁근종, 간경병 등 모든 병에서 게르마늄은 놀라운 효과를 나타내고 있다.Recently, as interest in organic germanium has been increased, he has been recognized as a functional healing substance due to his excellent efficacy. He has been highly appreciated as a functional healing substance and has been widely used as a therapeutic agent for lung cancer, bladder cancer, breast cancer, neurosis, asthma, diabetes, hypertension, heart failure, Germanium has a remarkable effect in all diseases such as cerebral palsy, uterine myoma, liver cirrhosis.
특히, 우리들 인간은 살아가기 위해서 음식물을 먹는데, 흡수되지 않은 것은 대변으로 배설되지만 소화기관에서 흡수된 것은 여러가지 과정을 거쳐 산소에 의해 체내에서 연소되며, 최후로 탄산가스와 물이 되어 체외로 배설, 즉, 가스상태의 탄소는 산소와 결합되어 탄산가스로서 호기에 의해 몸 밖으로 나오며, 또 하나의 가스인 수소이온은 산소와 결합되어 물로 땀이나 소변으로 배설되지만 수소는 양이온으로 생체내에서는 전혀 쓸모가 없으며 수소량이 많을수록 중화에 필요한 산소의 양도 많이 요구되므로 이런 경우 게르마늄을 투여하면 산소 대신 수소와 결합하여 배설되기 때문에 몸안의 산소가 낭비됨이 없이 기능회복, 세포수복등 본래의 역할, 건강에 절대적으로 필요한 역할을 하게 되는 것이다.In particular, we humans eat food to survive, but what is not absorbed is excreted in the feces, but what has been absorbed by the digestive organs is burned in the body by oxygen through various processes, and eventually becomes carbon dioxide and water, In other words, the carbon in the gaseous state is combined with oxygen and exits the body as a carbon dioxide gas. The hydrogen ion, which is another gas, is combined with oxygen and excreted in sweat or urine as water, but hydrogen is a cation and is useless in vivo In this case, when germanium is administered, it is excreted in combination with hydrogen instead of oxygen. Therefore, oxygen is not wasted in the body, and it is essential to restore function, restore cell integrity, As a result,
그러나, 이와 같은 게르마늄의 효능이 알려졌음에도 불구하고 아직까지 심층수와 병용하므로서 당뇨병에 우수한 치료 및 예방에 상승적인 효과가 발현된다는 사실은 보고된 바 없다.However, despite the fact that such germanium has been known to be effective, it has not been reported that a synergistic effect on the treatment and prevention of diabetes mellitus by combination with deep seawater still exists.
따라서, 본 발명의 목적은 정제된 심층수(선도액), 유기 게르마늄(Ge-132) 및 한약재를 주재료로 하여 건강보조식품으로서의 효능 뿐만 아니라 당뇨병에 우수한 치료 및 예방 효과를 나타내는 건강보조식품을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a dietary supplement that has excellent therapeutic and preventive effects on diabetes as well as efficacy as a dietary supplement, using purified deep-water (lead solution), organic germanium (Ge-132) There is.
본 발명의 다른 목적은 상기 목적의 건강보조식품을 용이하게 제조하는 방법을 제공하는 데 있다.Another object of the present invention is to provide a method for easily producing the above-mentioned health supplement.
상술한 목적들 뿐만 아니라 용이하게 표출될수 있는 또 다른 목적들을 달성하기 위하여 본 발명에서는 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 정제된 심층수(선도액) 60 ∼ 74.5중량%, 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상의 한약재 추출물 25 ∼ 39.5중량% 및 유기게르마늄(Ge-132) 0.5 ∼ 15중량%로 구성되어지되 정제된 심층수(선도액), 한약재 추출물 및 유기 게르마늄(Ge-132)을 혼합하여 본 발명의 건강보조식품을 얻고, 이를 복용하게 하므로서 당뇨병에 우수한 치료 및 예방 효과를 얻을 수 있었다..In order to achieve the above-mentioned objects as well as other objects which can be easily expressed, in the present invention, 60 to 74.5% by weight of purified deep water (lead solution) obtained by purifying deep sea water of 600 m deep and 1400 m deep sea water and mixing them at an appropriate ratio, Ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, chrysanthemum, corn oil, rock stone, ginseng, ginseng, pulp, taxa, omija, ginseng Consisting of gypsum, gyeongryeong, tianryun, gold, astronomy, quadruplet, in-situ gold, coexistence, deck, soil, ginseng, creation, ginseng, 25-39.5% by weight of at least six kinds of herbal extracts selected from the group consisting of germanium (Ge-132) and organic germanium (Ge-132) The mixture of the present invention By taking crude food and taking it, I was able to get excellent treatment and prevention effect on diabetes.
본 발명을 좀 더 상세히 설명하면 다음과 같다.The present invention will be described in more detail as follows.
본 발명에 따른 당뇨병에 우수한 치료 및 예방 효과를 갖는 건강보조식품은 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 정제된 심층수(선도액) 60 ∼ 74.5중량%, 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종이상의 한약재 추출물 25 ∼ 39.5중량% 및 유기 게르마늄(Ge-132) 0.5 ∼ 15중량%로 구성되는 것으로 특징지워진다.The health supplements having excellent therapeutic and preventive effects on diabetes according to the present invention comprise 60 to 74.5% by weight of purified deep water (purified liquid) obtained by purifying deep sea water of 600 m deep and 1400 m deep sea water and mixing them at an appropriate ratio, Ginseng, ginseng, gypsum, gypsum, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, chrysanthemum, ginseng, stone rock, ginseng, ginseng, pulses, taxa, omija, ginseng, gypsum At least one selected from the group consisting of ginseng, ginseng, ginseng, ginseng, baroojuk, gonorrhea, gougijie, phyllotaxis, licorice, chinchon, 25 to 39.5% by weight of 6 herbal extracts and 0.5 to 15% by weight of organic germanium (Ge-132).
또한, 본 발명에 따른 당뇨병의 치료와 예방에 효과적인 건강보조식품의 제조 방법은 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 다음에 별도로 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상의 한약재로부터 추출물을 얻은 후에 이를 정제하고, 정제된 심층수(선도액), 한약재 추출물 및 유기 게르마늄(Ge-132)을 균질하게 혼합하는 것으로 특징지워진다.본 발명은 해저 600m의 심층수와 1400m의 심층수를 정제하여 1:1 비율로 혼합한 정제된 심층수(선도액) 68중량%; 통초 10 중량부, 비파엽 30 중량부, 과루 12 중량부, 동과인 20 중량부, 두권 30 중량부, 행인 12 중량부, 쌍지 30 중량부, 의인 30 중량부, 차전초 30 중량부 및 활석 30 중량부를 열수 2340 중량부에 투입하여 열수 추출한 10%짜리 한약재 추출물 30 중량%; 및 카르복시 에틸 게르마늄 32 산화물 2 중량%로 구성되는 것을 특징으로 하는 당뇨병 치료 및 예방에 효과적인 건강보조식품에 관한 것이다. 또한 본 발명은 해저 600m의 심층수와 1400m의 심층수를 취하여 -4 ∼ 0℃의 온도를 유지하면서 1일간 정치하여 침전물을 제거한 후에 여과하는 방법으로 정제한 다음, 해저 600m의 심층수와 1400m의 심층수를 1 : 1의 비율로 혼합하는 단계; 통초 10 중량부, 비파엽 30 중량부, 과루 12 중량부, 동과인 20 중량부, 두권 30 중량부, 행인 12 중량부, 쌍지 30 중량부, 의인 30 중량부, 차전초 30 중량부 및 활석 30 중량부를 열수 2340 중량부에 투입하여 6시간 동안 열수 추출한 다음, 실온으로 냉각하고 1일간 정치한 후, 침전물을 제거하여 10% 짜리 한약재 추출물을 준비하는 단계; 상기 심층수(선도액) 혼합물 68중량%, 상기 한약재 추출물 30중량% 및 식물성 카르복시 에틸 게르마늄 32 산화물 2중량%를 혼합하고 교반하여 식물성 카르복시 에틸 게르마늄 32 산화물이 완전히 용해되고, 각각의 성분들이 균질하게 혼합되도록 하여 제조하는 것을 특징으로 하는 당뇨병 치료 및 예방에 효과적인 건강보조식품의 제조방법에 관한 것이다.In addition, the method for producing health supplements effective for the treatment and prevention of diabetes according to the present invention is characterized in that deep sea water of 600 m deep and 1400 m deep sea water are purified and mixed at an appropriate ratio, , Gyungsu, gyungsan, gypsum, gyeongryeong, gyeongsin, gyeonggwon, gyeonggwon, gyeongsin, gyeongsin, gyeonggwon, Extracts from at least six kinds of herbal medicines selected from the group consisting of insecticides, insecticides, intergrowths, coins, decks, earthworms, raw ginseng, creation of ginseng, confectionery, sewage, The present invention is characterized in that the deep seawater of 600 m in depth and the deep seawater of 1400 m in depth are purified to obtain 1 (1) : 68 wt% of purified deep water (lead solution) mixed at a ratio of 1: 1; 10 parts by weight of pine needle, 30 parts by weight of non-foliage, 12 parts by weight of overpowder, 20 parts by weight of copper and phosphorus, 30 parts by weight of two parts, 12 parts by weight of passerby, 30 parts by weight of twin, And 30% by weight of 10% herbal medicine extract obtained by adding hot water to 2340 parts by weight of hot water; And 2% by weight of carboxyethyl germanium 32. The present invention relates to a health supplement that is effective for the treatment and prevention of diabetes. In addition, the present invention is a method for recovering deep sea water from 600m deep and 1400m deep sea water by maintaining the temperature at -4 to 0 ° C for 1 day to remove precipitates and then filtering. : 1; 10 parts by weight of pine needle, 30 parts by weight of non-foliage, 12 parts by weight of overpowder, 20 parts by weight of copper and phosphorus, 30 parts by weight of two parts, 12 parts by weight of passerby, 30 parts by weight of twin, Was added to 2340 parts by weight of hot water for hot water extraction for 6 hours, cooled to room temperature, allowed to stand for 1 day, and then the precipitate was removed to prepare a 10% herbal extract; 68% by weight of the mixture of deep seawater (lead solution), 30% by weight of the herbal extract and 2% by weight of vegetable carboxyethyl germanium 32 oxide were mixed and stirred to completely dissolve the vegetable carboxyethyl germanium 32 oxide, The present invention relates to a method for producing a dietary supplement, which is effective for the treatment and prevention of diabetes.
본 발명에서 사용된 해저 600m의 심층수와 1400m의 심층수의 성분은 다음의 표 1과 같다.The components of deep seawater at 600 m deep and 1400 m deep seawater used in the present invention are shown in Table 1 below.
상기 표 1로부터 알 수 있는 바와 같이 심층수(선도액)에는 다양한 무기물 및 미량원소가 다량으로 함유되어 있고, 본 발명에서는 해저 600m의 심층수와 1400m의 심층수를 1 : 3 ∼ 3 : 1의 비율로 혼합하여 사용하였다.As can be seen from Table 1, deep seawater (lead solution) contains a large amount of various minerals and trace elements. In the present invention, deep seawater having a depth of 600 m and seawater having a depth of 1400 m are mixed at a ratio of 1: 3 to 3: 1 Respectively.
해저 600m의 심층수와 1400m의 심층수를 혼합하여 사용하는 것이 바람직하지만 해저 600m 이상의 심층수면 모두 사용이 가능하며, 심층수(선도액)는 대량의 미량원소와 미네랄 등을 포함하고 있을 뿐만 아니라 무기영양소금이 포함되어 있어 물부영양화 현상이 뚜렷하여 살아있는 조직(장기)의 신선도를 유지시켜주는 기능을 하기 때문에 효과적일 뿐만 아니라 인체에 균형을 유지케 하여 당뇨병의 원인을 치유케하며, 심층수(선도액)를 취하여 -4 ∼ 0℃의 온도를 유지하면서 1 ∼ 2일간 정치하여 침전물을 제거한 후에 여과하는 방법으로 정제한 것을 사용한다.It is preferable to use 600m of deep seawater and 1400m of deep seawater. However, deep seawater of 600m or more below sea bottom can be used. Deep seawater contains a large amount of trace elements and minerals, It is effective not only because it functions to maintain the freshness of living tissues (organs) because it has a phenomenon of water eutrophication, and it maintains a balance in the human body to heal the cause of diabetes and take deep water (lead solution) The solution is allowed to stand at a temperature of -4 to 0 ° C for 1 to 2 days to remove precipitates and then purified by filtration.
심층수(선도액)의 사용량은 60 ∼ 74.5중량%가 바람직하며, 사용량이 60중량% 미만일 경우에는 당뇨병에 우수한 치료 및 예방 효과가 만족스럽지 못하고, 74.5중량%를 초과할 경우에는 건강보조식품으로서의 효능이 저하되는 단점이 있다.The amount of the deep water (lead solution) is preferably 60 to 74.5% by weight, and when the amount is less than 60% by weight, excellent therapeutic and preventive effects against diabetes are unsatisfactory. When the amount exceeds 74.5% by weight, Is lowered.
유기 게르마늄(Ge-132)은 순도와 안전도가 매우 중요하며 체내에서의 소화흡수 또한 매우 중요하기 때문에 분말 형상인 것을 심층수(선도액)에 용해하여 사용하며, 분말의 상태가 순백색이고, 입자나 알갱이 같은 것이 없이 밀가루처럼 고우며, 분말의 상태가 덩어리처럼 뭉친 것이 없고, 불순물이 섞여 있지 않은 것을 사용하여야 하며, 60 ∼ 80℃의 물(증류수면 더 정확함) 50cc에 유기게르마늄 분말 20mg을 넣고 교반시 물에 완전히 용해되고, 용해후 오랜 시간이 지나도 침전물(불순물)이 생기지 않아야 하며, 물에 완전히 녹은 후에는 물이 크리스탈처럼 보통의 물보다 더 맑고 투명하게 되는 것을 선택하여 사용한다.Organic germanium (Ge-132) is very important for purity and safety, and its digestion and absorption in the body is also very important. Therefore, it is used by dissolving it in deep water (lead solution), and the state of the powder is pure white, It is recommended to use 20 g of organic germanium powder in 50 cc of water (distilled water is more accurate) at 60 to 80 ° C. When stirring, It should be completely dissolved in water and not precipitate (impurities) after a long time after dissolution. After it is completely dissolved in water, it should be selected so that water becomes clearer and transparent than normal water like crystal.
유기게르마늄이 함유하고 있는 산소는 세포안에서 발생기 산소로 방출되는데, 보통 산소는 통상적인 상태에서는 분자 O2의 형태로 존재하지만 다른 물질과 화합할 때는 산소원자 0의 형태가 되며, 유기게르마늄은 발생기 산소를 빈사직전의 세포에 방출시켜 세포를 부활시키므로서 대사활동이라는 세포내 화학반응을 활성화시키게 되고, 세포는 본래의 기능을 되찾아 싱싱하게 작용하게 되며, 결과적으로 온몸의 컨디션이 호전되어 당뇨병의 병인이 제거되는 것이다.Oxygen, which is contained in organic germanium, is released as a generator oxygen in the cell. Oxygen normally exists in the form of molecular O 2 in the normal state, but when it combines with other substances, it forms in the form of oxygen atom 0, Is released into the cell just before the vampire's death to revitalize the cell, thereby activating the intracellular chemical reaction called metabolic activity. The cell is restored to its original function and functions freshly. As a result, the condition of the whole body is improved, It is removed.
산의 바탕은 산소가 아니고 수소, 보다 정확하게 말하면 수소이온이고, 수소이온은 체내에서 쓸모가 전혀 없는 가스에 불과하지만 그것이 정도 이상으로 축적되면 체질이 산성화되었다고 하며, 컨디션을 무너뜨리는 계기가 되는 데, 이 불필요한 가스를 청소하는데 산소가 필요하며, 산소는 필요없는 수소이온과 결합하여 중성인 물이 되어 몸밖으로 배설되는데 유기게르마늄은 그것을 위한 산소를 공급하는 작용을 하며, 수은이나 카드뮴같은 유해한 중금속을 동반해서 체외로 배설시켜주는 역할을 한다.The background of the acid is not oxygen but hydrogen, or more precisely, hydrogen ion. Hydrogen ion is only a gas that is useless in the body, but when it accumulates above the level, it is said that the constitution is acidified, Oxygen is needed to clean up this unnecessary gas, and oxygen combines with unnecessary hydrogen ions to form neutral water, which is excreted out of the body. Organic germanium acts to supply oxygen for it, and harmful heavy metals such as mercury and cadmium And excreted in vitro.
본 발명에서는 버섯, 고려인삼, 밤, 구기자 열매 등과 같이 게르마늄이 고단위로 함유되어 있는 식용 가능한 식물로부터 분리한 것으로, 마늘, 컴프리, 알로에, 표고버섯같은 버섯류도 유기 게르마늄(Ge-132)원으로 사용될 수 있으며, "카르복시 에틸 게르마늄 32산화물"(분자식 : (GeCH2CH2COOH)2O3)이 특히 효과적이다.In the present invention, mushrooms such as garlic, comfrey, aloe, and shiitake mushroom, which are separated from edible plants containing high-germanium such as mushroom, Korean ginseng, chestnut, and goji berries, are also used as organic germanium (Ge-132) And "Carboxyethylgermanium 32 oxide" (molecular formula: (GeCH 2 CH 2 COOH) 2 O 3 ) is particularly effective.
유기 게르마늄(Ge-132)의 사용량은 0.5 ∼ 15중량%가 바람직하며, 사용량이 0.5중량% 미만일 경우에는 유기 게르마늄(Ge-132)의 효과 발현이 미약한 단점이 있고, 사용량이 15중량%를 초과할 경우에는 첨가 상승효과가 미약하여 경제적이지 못한 단점이 있다.The use amount of organic germanium (Ge-132) is preferably 0.5 to 15% by weight. When the amount is less than 0.5% by weight, the effect of organic germanium (Ge-132) There is a disadvantage in that the effect of synergistic addition is weak and it is not economical.
한편, 한약재는 당뇨병에 우수한 치료 및 예방에 효능이 있는 것으로 알려져 있는 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문등, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상을 사용하되, 상호 효능이 상승 작용을 하는 것들을 사용하며, 한약재를 열수 추출하여 정치한 다음 여과한 것이 효과적이고, 한약재의 사용량은 25 ∼ 39.5중량%가 바람직하며, 사용량이 25중량% 미만일 경우에는 건강 보조 식품으로서의 효능 발현이 미약한 단점이 있고, 39.5중량%를 초과할 경우에는 심층수(선도액)와 유기 게르마늄(Ge-132)의 사용량이 상대적으로 감소되어 당뇨병에 우수한 치료 및 예방 효과가 미약한 단점이 있다.On the other hand, Chinese medicinal herbs have been widely used for the treatment and prevention of diabetes, such as herbaceous, non-fructus, overgrown, Ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, ginseng, At least six kinds selected from the group consisting of barbuda jaeba, mandarin jaeba, gugija, phyllotaxis, licorice, jongdong, and red mulberry are used, and those having mutual effect synergy are used, and the herbal medicines are extracted with hot water, The amount of the herbal medicine is preferably 25 to 39.5% by weight. When the amount of the herbal medicine is less than 25% by weight, the efficacy as a health supplement food is weak. On the other hand, when it exceeds 39.5% The amount of the liquid) and the organic germanium (Ge-132) is reduced to relatively have an excellent therapeutic and preventive effects are slight disadvantage in diabetes.
본 발명의 건강보조식품은 작용기전이 정확히 밝혀지지 않았지만 당뇨병의 치료와 예방에 우수한 효과를 나타내었다.The health supplements of the present invention showed excellent effects on the treatment and prevention of diabetes although its mechanism of action was not clearly known.
다음의 실시예는 본 발명을 좀 더 상세히 설명하는 것이지만, 본 발명의 범주를 한정하는 것은 아니다.The following examples illustrate the invention in more detail but do not limit the scope of the invention.
실시예 1Example 1
해저 600m의 심층수와 1400m의 심층수를 취하여 -4 ∼ 0℃의 온도를 유지하면서 1일간 정치하여 침전물을 제거한 후에 여과하는 방법으로 정제한 다음, 해저 600m의 심층수와 1400m의 심층수를 1 : 1의 비율로 혼합한다.Deep seawater of 600 m in depth and 1400 m of deep seawater were taken at a temperature of -4 to 0 ° C for one day to remove precipitates and then filtered to obtain a deep sea water having a depth of 600 m and a deep sea water having a depth of 1: .
별도로 통초 10g, 비파엽 30g, 과루 12g, 동과인 20g, 두권 30g, 행인 12g, 쌍지 30g, 의인 30g, 차전초 30g, 활석 30g을 열수 2340 중량부에 투입하여 6시간 동안 열수 추출한 다음, 실온으로 냉각하고 1일간 정치한 후, 침전물을 제거하여 10%짜리 한약재 추출물을 준비하였다.Separately, the mixture was added to 2340 parts by weight of hot water, and the mixture was subjected to hot water extraction for 6 hours, followed by cooling to room temperature After standing for 1 day, the precipitate was removed to prepare a 10% herbal extract.
그 다음에 상기 심층수(선도액) 혼합물 68중량%, 상기 한약재 추출물 30중량%와 식물성 카르복시 에틸 게르마늄 32산화물 2중량%를 혼합하고 교반하여 식물성 카르복시 에틸 게르마늄 32산화물이 완전히 용해되고, 각각의 성분들이 균질하게 혼합되도록 하여 본 발명의 당뇨병 치료 및 예방에 효과적인 건강보조식품을 제조하였다.Then, 68 wt% of the mixture of the deep sea water (lead solution), 30 wt% of the herbal extract and 2 wt% of the vegetable carboxyethyl germanium 32 oxide were mixed and stirred to completely dissolve the vegetable carboxyethyl germanium 32 oxide, To thereby produce a health supplement which is effective for the treatment and prevention of diabetes according to the present invention.
실시예 2Example 2
한약재로 표 2에 기재된 것을 사용한 것을 제외하고는 실시예 1과 동일하게 행하여 건강보조식품을 제조하였다.A dietary supplement was prepared in the same manner as in Example 1, except that the medicinal materials listed in Table 2 were used.
실험예 1Experimental Example 1
본 발명에 따른 건강보조식품의 인체에 대한 무독성을 입증하기 위하여 마우스를 대상으로 급성독성시험을 실시하였다.To demonstrate the non-toxicity of the dietary supplement according to the present invention on the human body, an acute toxicity test was conducted on mice.
[급성독성시험][Acute toxicity test]
(1) 재료 및 방법(1) Materials and methods
가) 실험동물A) Experimental animals
1) 종(계통) : ICR계 마우스(ICR mouse)1) Species: ICR mouse (ICR mouse)
2) 성별 및 입수시 주령 : 수컷 4주령2) Gender and age at the time of arrival: 4-week-old male
3) 선택이유 : 본 실험에 사용된 ICR계 마우스는 전세계적으로 독성시험에 널리 사용되어 왔기 때문에 생리, 해부 및 독성학적 기초자료가 풍부하여 그 결과를 비교하기가 유리하고 또한 실험동물의 구입 및 사용이 편리하여 선택하였다.3) Reason for selection: Since ICR mice used in this experiment have been widely used in toxicity tests globally, it is advantageous to compare the results with abundant physiological, anatomical and toxicological data, It was chosen because it was easy to use.
4) 공급원 : 대륙시험동물4) Source: Continental test animals
5) 검역 및 순화기간 : 실험실에 순화시키는 기간을 약 1주일 두었으며, 그 기간중 일반증상을 관찰하여 건강한 동물만을시험에 사용하였다.5) Quarantine and refinement period: The period of refinement in the laboratory was about one week. During the period, general symptoms were observed and only healthy animals were used for the test.
6) 정맥주사시 체중범위 및 주령 : 20± 3g, 5주령6) Intravenous weight range and weight: 20 ± 3g, 5 weeks
7) 사용동물수 : 100마리(예비시험 포함)7) Number of animals used: 100 (including preliminary test)
8) 군 분리 및 동물시별 : 시험에 사용된 건강한 동물의 체중을 측정하여 각군의 평균체중이 거의 일치하도록 군 분리를하였고, 개체식별은 피모색소(피크린산) 마킹법과 사육상자별 TAG 표시법을 이용하였다.8) Group separation and animal age: The body weights of the healthy animals used in the test were measured, and the group was separated so that the average weight of each group was almost identical. The individual identification was performed using the pigmented pigment (picric acid) Respectively.
나) 동물실B) Animal room
1) 온, 습도범위 : 온도 22± 2℃, 상대습도 53± 2%1) Temperature, humidity range: 22 ± 2 ℃, relative humidity 53 ± 2%
2) 명암 사이클 : 형광등조명(09:00 점등~18:00 소등)2) Contrast Cycle: Fluorescent lighting (09:00 lights up ~ 18:00 lights off)
3) 조도 : 150~300Lux3) Illumination: 150 ~ 300Lux
4) 사육상자의 종류 : 순화, 검역, 투여 및 관찰기간 중 마우스용 플리카보네이트(polycarbonate)케이지(대종기계제작)4) Types of breeding boxes: Polycarbonate cage for mice (manufactured by Dae Jong Machinery) during the purification, quarantine,
5) 사육상자당 동물수 : 순화, 검역기간 -5마리5) Number of animals per breeding box: Purification, quarantine period -5 grains
투여기간-5마리Duration of administration - 5 grains
다) 사료C) Feed
1) 종류 : 실험동물용 고형사료1) Type: Solid feed for laboratory animals
2) 공급원 : 삼양유지사료주식회사2) Sources: Samyang Hengyu Feed Co., Ltd.
라) 음수D) Negative
1) 종류 : 여과된 수도수1) Type: Filtered water
마) 시험물질E) Test substance
1) 시료 : 상기 실시예 1에서 제조된 조성물(1000배 희석액)1) Sample: The composition (1000-fold dilution) prepared in Example 1 above,
공시험액(음성대조군)The blank test solution (negative control)
바) 투여방법F) Method of administration
1) 투여경로 : 경구투여(Oral)1) Route of Administration: Oral (oral)
2) 투여회수 및 투여기간 : 1회투여2) Number of doses and duration of administration: Single dose
3) 투여부위 및 투여법 : 마우스에 경구투여하였다.3) Administration site and administration method: Oral administration to mice.
4) 투여시각 : 10:00~12:004) Administration time: 10:00 to 12:00
5) 투여량 : 투여직전에 체중을 기준으로 하여 50ml/kg를 투여하였다.5) Dose: Immediately before administration, 50 ml / kg was administered based on body weight.
(2) 시험방법(2) Test method
가) 국립보건원 독성시험에 따라 실시하였다.A) In accordance with the National Institute of Health's toxicity test.
나) 임상증상관찰 : 전 동물에 대하여 매일 실시하였다.B) Observation of clinical symptoms: All animals were treated daily.
투여 후 6시간은 매시간 관찰하여 그후 5일간 1일 1회 운동성, 외관 및 자율신경증상을 주의 깊게 관찰하였다.After 6 hours of administration, the mice were observed every hour, and then mobility, appearance, and autonomic symptoms were carefully observed once a day for 5 days.
(3) 시험결과(3) Test results
이상의 결과에서 알 수 있는 바와 같이, 본 발명 실시예의 건강보조식품과 음성대조군의 경구투여 후 2주간의 관찰 결과, 체중과 운동성이 정상적인 것으로 관찰되었다.As can be seen from the above results, it was observed that the body weight and motility were normal in the two weeks after the oral administration of the health supplement and the negative control of the example of the present invention.
실험예 2Experimental Example 2
* 실시예 1의 건강보조식품이 정상 새끼쥐에 미치는 혈당강하효과* The blood glucose lowering effect of the dietary supplement of Example 1 on normal rat
체중이 20 ± 2g의 흰 새끼쥐 40마리를 1조에 10마리씩 4조로 나누어 넣고, 약물이 투여되지 않은 정상조에는 당량의 생리식염수를 복강에 투여하고, 약물조에는 글리벤클라마이드(Glibenclamide)를 새끼쥐 복강에 5mg/kg을 투여하고, 실시예 1의 건강보조식품 투여조에는 실시예 1에서 제조된 건강보조식품 2g/kg과 1g/kg을 각각 새끼쥐 복강에 15일 동안 투여하였다. 약을 투여하기 전과 약을 투여한 지 15일 후, 쥐꼬리에서 0.05㎖ 정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 공복시의 혈당치를 측정하였다. 측정된 결과는 표 4에 나타내었다.Forty (40 ± 2) grams of a 20 ± 2 g rat were divided into four groups of 10 in each group. The equivalent of normal saline was administered to the abdominal cavity, and glibenclamide (Glibenclamide) was added to the abdominal cavity 5 g / kg of the dietary supplement prepared in Example 1, and 2 g / kg of the health food prepared in Example 1 and 1 g / kg of the dietary supplement of Example 1 were administered to the rat peritoneal cavity for 15 days, respectively. Before the administration of the drug and 15 days after the administration of the drug, 0.05 ml of blood was collected from the rat tail, and the fasting blood glucose level was measured using the US JD2DGA7CC microglycemia measuring device. The measured results are shown in Table 4.
상기 표 4에 기재된 결과로 부터 알 수 있는 바와 같이, 본 발명의 건강보조식품은 기존에 이미 당뇨병 치료제로서의 효능이 입증되어 있는 글리벤클라마이드와 마찬가지로 정상 새끼쥐에서 혈당강하효과를 나타낸다.As can be seen from the results shown in Table 4, the health supplement of the present invention exhibits a blood glucose lowering effect in normal rat rats as in the case of glibenclamide, which has already been proven as a therapeutic agent for diabetes.
실험예 3Experimental Example 3
* 본 발명의 건강보조식품 알록손 투여된 당뇨병 새끼쥐에게 미치는 혈당강하 효과* The hypoglycemic effect of the dietary supplemental food of the present invention
체중이 20 ± 2g의 흰 새끼쥐 암수를 함께 실험하였다. 실험 전에 12시간 동안 금식시키고, 정상조를 제외한 각조에 신선하게 배합하여 만든 2%의 알록손용액 200mg/kg을 복강에 주사하였다. 48시간 후, 12시간 금식시킨 동물의 공복혈당뇨를 측정하여 16.67mmol/L를 초과한 당뇨병의 새끼쥐 40마리를 1조에 10마리씩 4조로 나누었다. 정상조 10마리는 알록손을 투여하지 않았다. 정상조와 모형조에는 당량의 생리식염수를 복강에 투여하고, 약물조에는 글리벤클라마이드를 새끼쥐 복강에5 mg/kg을 투여하고, 본 발명의 건강보조식품 투여조에는 본 발명의 조성물 2g/kg과 1g/kg을 각각 새끼쥐 복강에 15일 동안 투여하였다. 약을 투여하기 전과 약을 투여한 지 15일 후, 쥐꼬리에서 0.05㎖ 정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 공복시의 혈당치를 측정하였다. 측정된 결과는 표 5에 나타내었다.The male and female white rats weighing 20 ± 2g were tested together. Before the experiment, the animals were fasted for 12 hours and 200 mg / kg of 2% aloxon solution prepared freshly in each group except the steers were injected into the abdominal cavity. Forty-eight hours later, animals fasting for 12 hours were measured for fasting blood glucose. Forty diabetic rats, exceeding 16.67 mmol / L, were divided into four groups of 10 rats each. Ten dogs did not administer Allotson. To the test group and the model group, an equivalent amount of physiological saline was administered to the peritoneal cavity. Glybenclamide was administered to the abdominal cavity of the mice at a dose of 5 mg / kg. In the health supplementary administration group of the present invention, 2 g / kg of the composition of the present invention and 1 g / kg < / RTI > was administered to the rat peritoneal cavity for 15 days. Before the administration of the drug and 15 days after the administration of the drug, 0.05 ml of blood was collected from the rat tail, and the fasting blood glucose level was measured using the US JD2DGA7CC microglycemia measuring device. The measured results are shown in Table 5.
상기 표 5에 기재된 결과로 부터, 본 발명의 건강보조식품은 기존에 이미 당뇨병 치료제로서의 효능이 입증되어 있는 글리벤클라마이드와 마찬가지로 알록손 투여된 당뇨병 새끼쥐에서 혈당을 현저하게 저하시키는 것을 알 수 있다.From the results shown in Table 5, it can be seen that the dietary supplement of the present invention significantly lowered blood glucose levels in diabetic mice administered with alloxan as well as glibenclamide, which has already proven its efficacy as a therapeutic agent for diabetes.
알록손이 유리기 OH를 생성하면, 담낭이 지나치게 산화되어 인슐린 베타 세포가 상하게 되므로써 당뇨병을 유발하게 되는데, 본 발명의 건강보조식품은 이와같은 베타세포에 손상 입히는 작용을 감소시켜 인슐린을 정상으로 회복시킨다.When Allofson generates free radicals OH, the gallbladder is excessively oxidized and the insulin beta cells are injured, resulting in diabetes. The health supplement of the present invention reduces the damage to the beta cells and restores insulin to normal state .
실험예 4Experimental Example 4
* 본 발명의 건강보조식품이 아드레날린 투여된 큰쥐에게 미치는 혈당강하효과* The hypoglycemic effect of the dietary supplement of the present invention on adrenaline-infused mice
체중이 180 ± 20g의 위스터 숫컷 큰쥐 50마리를 1조에 10마리씩 5조로 나누었다. 실험 전에 24시간 동안 금식시키고, 정상조를 제외한 각조 쥐의 피하에 0.1% 아드레날린 0.2㎖/kg을 주사하고, 정상조의 피하에 같은 양의 생리식염수를 주사하고, 각조의 피하에 같은 양의 생리식염수를 주사한 다음 바로 다른 약물을 복강에 투여하였다. 90분, 130분 후에 각각 큰쥐의 꼬리에서 모두 0.05㎖정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 혈당치를 측정하고, 각조별로 비교하였다. 측정된 결과는 표 6에 나타내었다.Fifty male Wistar rats weighing 180 ± 20 g were divided into 5 groups of 10 rats each. The mice were fasted for 24 hours before the experiment and injected 0.2 ml / kg of 0.1% adrenaline into the subcutaneous tissues of the mice except for the control group. The same amount of physiological saline was injected subcutaneously into the subcutaneous tissues and the same amount of physiological saline Immediately after the injection, another drug was administered intraperitoneally. 90 minutes, and 130 minutes, blood was collected from the tail of each rat at a dose of 0.05 ml, and the blood glucose level was measured using a US type JD2DGA7CC microglycemia meter. The measured results are shown in Table 6.
상기 표 6에 기재된 결과로부터, 본 발명의 건강보조식품은 정상 새끼쥐의 혈당은 거의 저하시키지 않으면서, 아드레날린 당뇨병큰쥐의 혈당은 저하시키는 것을 알 수 있다.From the results shown in Table 6, it can be seen that the dietary supplement of the present invention lowers the blood sugar of adrenaline-induced diabetic rats while substantially reducing the blood glucose of normal rats.
상술한 바와 같이 본 발명에서는 해저 600m의 심층수와 1400m의 심층수를 정제하여 적정한 비율로 혼합한 정제된 심층수(선도액) 60 ∼ 74.5중량%, 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 홍매 등으로 구성되는 군으로부터 선택된 적어도 6종 이상의 한약재 추출물 25 ∼ 39.5중량% 및 유기게르마늄(Ge-132) 0.5 ∼ 15중량%로 구성되어지되 정제된 심층수(선도액), 한약재 추출물 및 유기 게르마늄(Ge-132)을 혼합하여 본 발명의 건강보조식품을 얻고, 이를 복용하게 하므로서 당뇨병에 우수한 치료 및 예방 효과를 얻을 수 있었다.As described above, in the present invention, 60 to 74.5% by weight of purified deep water (purified liquid) obtained by purifying deep sea water having a depth of 600 m and deep sea water having a depth of 1,400 m, Silla, Sangjin, Chinchon, Talc, Talcum, Biogeji, Jiwon, Life Crest, Changgeun, Cheonhwabun, Sansui, Rock Stone, Jiam, Samshan, Pulse, Taxa, Omija, Gyosan, Plaster, Bokryeong, Cheonryun, Golden 25 to 39.5% by weight of at least six kinds of medicinal plant extracts selected from the group consisting of gold, copper, deck, soil, ginseng, creation, ginseng, And the organic germanium (Ge-132), and 0.5 to 15% by weight of organic germanium (Ge-132) are mixed with the purified water (purified liquid), herbal medicine extract and organic germanium Excellent Treatment and Examples for Diabetes It was able to get the effect.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0057661A KR100486963B1 (en) | 2002-09-23 | 2002-09-23 | The health-supporting food having the effect of diabetes mellitus and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0057661A KR100486963B1 (en) | 2002-09-23 | 2002-09-23 | The health-supporting food having the effect of diabetes mellitus and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040026276A KR20040026276A (en) | 2004-03-31 |
KR100486963B1 true KR100486963B1 (en) | 2005-05-03 |
Family
ID=37328772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0057661A KR100486963B1 (en) | 2002-09-23 | 2002-09-23 | The health-supporting food having the effect of diabetes mellitus and its preparation method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100486963B1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100712659B1 (en) * | 2005-08-31 | 2007-05-02 | 정두수 | Herbal composition for treatment and prevention of diabetes and diabetic complications |
KR100854700B1 (en) * | 2008-01-16 | 2008-08-27 | 주식회사 한국인삼공사 | Functional beverages composing ginseng steamed red concentrated solution |
CN107668699A (en) * | 2017-10-27 | 2018-02-09 | 刘伟伟 | A kind of diabetes clinical nutrition formula and preparation method thereof |
CN110973604A (en) * | 2019-11-22 | 2020-04-10 | 坤承(北京)健康管理有限公司 | Cereal meal replacement powder for diabetics to eat |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960003738A (en) * | 1994-07-01 | 1996-02-23 | 한동근 | Health and nutritional composition with improvement effect on diabetes |
KR970068894A (en) * | 1996-04-24 | 1997-11-17 | 강대일 · 정영숙 | Health food composition containing minerals, herbal medicine extracts and amino acids |
JP2002119263A (en) * | 2000-10-16 | 2002-04-23 | Kazuhiro Kotani | Sport drink utilizing ocean deep water |
KR20020045598A (en) * | 2002-05-29 | 2002-06-19 | 최형태 | Food and drinking water manufacture method to add deepsea water |
-
2002
- 2002-09-23 KR KR10-2002-0057661A patent/KR100486963B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960003738A (en) * | 1994-07-01 | 1996-02-23 | 한동근 | Health and nutritional composition with improvement effect on diabetes |
KR970068894A (en) * | 1996-04-24 | 1997-11-17 | 강대일 · 정영숙 | Health food composition containing minerals, herbal medicine extracts and amino acids |
JP2002119263A (en) * | 2000-10-16 | 2002-04-23 | Kazuhiro Kotani | Sport drink utilizing ocean deep water |
KR20020045598A (en) * | 2002-05-29 | 2002-06-19 | 최형태 | Food and drinking water manufacture method to add deepsea water |
Also Published As
Publication number | Publication date |
---|---|
KR20040026276A (en) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Akhtar et al. | Evaluation of the hypoglycaemic effect of Achyranthes aspera in normal and alloxan-diabetic rabbits | |
US20200038435A1 (en) | Mineral, nutritional, cosmetic, pharmaceutical, and agricultural compositions and methods for producing the same | |
KR101870846B1 (en) | Multi-functional composition and preparation method and application thereof | |
CN103355655A (en) | Composition with alimentary anemia improving function and preparation method of composition | |
KR100486963B1 (en) | The health-supporting food having the effect of diabetes mellitus and its preparation method | |
CN104352624B (en) | Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared | |
KR101775087B1 (en) | A composition for the prevention or treatment of stress or depression containing mulberrofuran G, sanggenon G and sanggenol A | |
KR20040000046A (en) | The health-supporting food being effective the atopic dermatitis and its preparation method | |
KR100486961B1 (en) | The health-supporting food being effective the sexual energy strength and its preparat ion method | |
KR101958969B1 (en) | A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant | |
KR100475196B1 (en) | The health-supporting food being effective the hairloss preventation or hair-growth and its preparation method | |
CN102178718B (en) | Preparation used for treating diabetes mellitus and preventively treating heart cerebrovascular disease | |
CN101019897B (en) | Antitumor medicine composition and its preparation method | |
CN112546032B (en) | New application of phloretin | |
KR100486960B1 (en) | The health-supporting food being effective the hypertension and its preparation method | |
CN1259851C (en) | sunflower extract product | |
KR101072904B1 (en) | Compositions for preventing obesity) | |
KR100526639B1 (en) | The health-supporting food having the effect of anti-tumor and its preparation method | |
KR20040026273A (en) | The health-supporting food being effective the dementia and its preparation method | |
Srivastava et al. | COMPARATIVE ANALYSIS OF HAEMATINIC EFFECT OF DHATRYARISTA WITH STANDARD FERROUS SULPHATE IN TANNIC ACID INDUCED IRON DEFICIENCY ANAEMIA IN ALBINO WISTAR RATS | |
KR20040003719A (en) | The health-supporting food being effective for diet and its preparation method | |
CN107308235A (en) | A kind of Chinese medicine composition and preparation method for preventing and treating chicken coccidiasis | |
KR101958975B1 (en) | A composition for improving, preventing and treating of fatty liver diseases comprising a complex extract of seaweed and complex extract of plant | |
US9895409B2 (en) | Remedy for gastritis and gastric ulcer | |
KR20040003720A (en) | The health-supporting food being effective for treatment of constipation and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130416 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140425 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150423 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160425 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170425 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180625 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190423 Year of fee payment: 15 |